PHOSPHOMANNOMUTASE 2 CONGENITAL DISORDER OF GLYCOSYLATION

Clinical trials for PHOSPHOMANNOMUTASE 2 CONGENITAL DISORDER OF GLYCOSYLATION explained in plain language.

Never miss a new study

Get alerted when new PHOSPHOMANNOMUTASE 2 CONGENITAL DISORDER OF GLYCOSYLATION trials appear

Sign up with your email to follow new studies for PHOSPHOMANNOMUTASE 2 CONGENITAL DISORDER OF GLYCOSYLATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Promising PMM2-CDG drug trial halted early

Disease control Terminated

This study tested an oral drug called epalrestat in children aged 2 to 17 with PMM2-CDG, a rare genetic disorder that affects how the body makes certain proteins. The goal was to see if the drug could improve symptoms and lab markers compared to a placebo. The trial was terminate…

Matched conditions: PHOSPHOMANNOMUTASE 2 CONGENITAL DISORDER OF GLYCOSYLATION

Phase: PHASE3 • Sponsor: Maggie's Pearl, LLC • Aim: Disease control

Last updated Apr 24, 2026 16:05 UTC

PHOSPHOMANNOMUTASE 2 CONGENITAL DISORDER OF GLYCOSYLATION

Get alerted when new PHOSPHOMANNOMUTASE 2 CONGENITAL DISORDER OF GLYCOSYLATION trials appear

Promising PMM2-CDG drug trial halted early